| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958446 | SANDOZ | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) | |
| US5474783 | SANDOZ | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) | |
| US6024976 | SANDOZ | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan, 2014
(10 years ago) | |
| US5656286 | SANDOZ | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug, 2014
(9 years ago) | |
Vivelle-Dot is owned by Sandoz.
Vivelle-Dot contains Estradiol.
Vivelle-Dot has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Vivelle-Dot are:
- US5958446
- US5474783
- US6024976
- US5656286
Vivelle-Dot was authorised for market use on 03 May, 2002.
Vivelle-Dot is available in system;transdermal dosage forms.
The generics of Vivelle-Dot are possible to be released after 12 August, 2014.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 03 May, 2002
Treatment: NA
Dosage: SYSTEM;TRANSDERMAL
How can I launch a generic of VIVELLE-DOT before it's drug patent expiration?
More Information on Dosage
VIVELLE-DOT family patents
